Skip to main content

Table 1 Demographic, clinical and CMR data from the studied cohorts

From: Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance

 

Healthy subjects (33 pts)

Athletes (22 pts)

HHD (228 pts)

HCM (45 pts)

Amyloidosis (41 pts)

p values*

Age (years)

31.7 ± 10

37.1 ± 11

66.2 ± 11

56 ± 15

71.4 ± 11

< 0.001

Female sex

13 (39%)

7 (32%)

74 (32%)

17 (38%)

3 (7%)

0.01

Arterial hypertension

0 (0%)

0 (0%)

228 (100%)

30 (67%)

25 (61%)

< 0.001

Diabetes mellitus

0 (0%)

1 (4%)

53 (19%)

8 (18%)

5 (12%)

< 0.001

BMI (Kg/m2)

23.9 ± 5.6

22 ± 2.5

28.2 ± 4.8

27 ± 4.4

24.4 ± 2.5

< 0.001

BSA (m2)

1.8 ± 0.2

1.9 ± 0.2

2 ± 0.2

2 ± 0.2

1.9 ± 0.2

< 0.01

LVEDV (ml)

183.6 ± 46

206.2 ± 43

166.5 ± 41

171 ± 38

181.3 ± 42

0.001

LVEDV index (ml/m2)

89 ± 20

107.3 ± 16

82.3 ± 17

86 ± 17.1

94.1 ± 21

0.001

LVESV (ml)

60 ± 19

85.2 ± 28

66.4 ± 29

72.3 ± 54

85.6 ± 33

< 0.01

LVESV index (ml/m2)

32.4 ± 8

44 ± 11

32.5 ± 12

32.4 ± 11

44.2 ± 17

< 0.001

LV ejection fraction

59.2 ± 5

55 ± 7

55 ± 8.5

56 ± 10

50 ± 10

< 0.01

Stroke volume (ml)

109 ± 31

112 ± 24

91 ± 23

95 ± 29

91 ± 24

< 0.001

Stroke volume index (ml/m2)

51 ± 12

59 ± 11

45 ± 11

48 ± 12

47 ± 12

< 0.001

IVS (mm)

7.6 ± 1.7

9 ± 2

12 ± 1.8

17.4 ± 6

17.4 ± 3.3

< 0.001

Lateral wall (mm)

5.2 ± 1.5

6.8 ± 2.3

8 ± 2

8.7 ± 3

12.3 ± 3.5

< 0.001

LV mass (g)

108.2 ± 24

134.2 ± 30

130 ± 30

154 ± 50.6

184.1 ± 45

< 0.001

LV mass index (g/m2)

56.1 ± 11

69.5 ± 11

64.2 ± 13

76.8 ± 21

95 ± 21

< 0.001

MCF

1.07 ± 0.23

0.91 ± 0.21

0.75 ± 0.17

0.69 ± 0.21

0.55 ± 0.19

< 0.001

LV concentricity

0.69 ± 0.1

0.68 ± 0.12

0.84 ± 0.17

0.96 ± 0.25

1.14 ± 0.25

< 0.001

T1 (ms)

1052 ± 27

1041 ± 42

1054 ± 44

1079 ± 61

1175 ± 65

< 0.001

Atypical LGE present

0 (0%)

3 (14%)

81 (36%)

44 (98%)

37 (90%)

< 0.001

Diffuse LGE present

0 (0%)

0 (0%)

25 (11%)

21 (47%)

37 (90%)

< 0.01

Focal intramyocardial LGE

0 (0%)

2 (9%)

32 (14%)

21 (47%)

0 (0%)

< 0.01

Focal epicardial LGE

0 (0%)

1 (5%)

24 (11%)

2 (5%)

0 (0%)

< 0.05

Distribution of focal vs. diffuse LGE

N.A

1.0 ± 0

1.2 ± 0.4

1.5 ± 0.5

2.0 ± 0

< 0.001

Atypical LGE score

1.00 ± 0

1.03 ± 0.09

1.06 ± 0.09

1.25 ± 0.19

1.75 ± 0.39

< 0.001

GLS(%)

− 20.9 ± 1.2

− 20.2 ± 1.2

− 18.8 ± 2.1

− 14.7 ± 3.5

− 12.2 ± 3

< 0.001

GCS(%)

− 20.2 ± 1.6

− 19.9 ± 1.3

− 17.8 ± 1.8

− 16.3 ± 2.2

− 14.1 ± 2.6

< 0.001

%normal myocardium

0.85 ± 0.06

0.83 ± 0.06

0.66 ± 0.15

0.48 ± 0.15

0.27 ± 0.18

< 0.001

  1. BMI body-mass-index, BSA body surface area, LV left ventricle, EDV end-diastolic-volume, ESV end-systolic-volume, IVS intraventricular septum, LGE late gadolinium enhancement, GLS global longitudinal strain, GCS global circumferential strain, MCF myocardial contraction fraction, N.A. not applicable
  2. LV concentricity was calculated as a ratio of LV mass divided by LVEDV
  3. *Statistical significance remained after adjustment for the co-variates “age” and “sex”
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us